Classical Swine Fever (CSF) remains a highly transmissible viral threat to the Suidae family with considerable economic consequences worldwide. The current study developed and comprehensively validated an indirect ELISA that uses the recombinant E2 protein (rE2) from CSFV. The amplified 546 bp segment from the N-terminal of the CSFV E2 gene, cloned into the pET-28a vector, and introduced into E. coli TOP10 and subsequently into BL21(DE3) cells. A ~25 kDa His-tagged rE2 protein was successfully expressed, followed by solubility analysis and purified using affinity chromatography. The recombinant protein was verified by Western blot analysis employing anti-His antibodies and CSFV positive pig sera. Using 500 pig serum samples, the developed iELISA diagnostic performance was evaluated and compared with both an indigenously developed E^rns ELISA kit and Priocheck CSFV Antibody ELISA kit. ROC analysis of developed rE2 iELISA demonstrated robust diagnostic precision, yielding an area under the curve (AUC) value of 0.935 (92% sensitivity, 90% specificity; cut-off 0.5695) against the Priocheck CSFV Antibody ELISA kit and with indigenously developed E^rns ELISA assay (AUC 0.995; 97.98% sensitivity; 96.97% specificity at the cut-off of 0.404). A statistically significant variation in diagnostic accuracy of two assays was evident in comparative ROC curve analysis (AUC difference = 0.216; SE = 0.0482; 95% CI: 0.122-0.311; z = 4.484; P < 0.0001) proving the developed assay provides a sensitive, specific, and robust serological tool suitable for CSF serosurveillance.